E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000519 |
E.1.2 | Term | Acne vulgaris |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of Duac Akne Gel compared with Epiduo Gel in the treatment of facial acne vulgaris by assessing the percent change in inflammatory lesion count (papules and pustules, including nasal lesions) from baseline to week 12. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety and tolerability of Duac Akne Gel compared with Epiduo Gel. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects who are males or females 12 to 45 years of age, inclusive, in good general health. 2. Subjects who are capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed. NOTE - Subjects under 18 years of age must provide assent and have the written, informed consent of the parent(s) or legal guardian responsible for their custody. 3. Subjects who are willing to follow therapeutic instructions including avoidance of any other topical facial or systemic acne therapy during the conduct of the study. 4. Subjects who have: A minimum of 25 to a maximum of 80 inflammatory facial lesions (papules and pustules), including the nose, and no facial nodular cystic lesions. AND A minimum of 12 to a maximum of 100 non-inflammatory facial lesions (open and closed comedones), excluding the nasal area. 5. Female subjects of childbearing potential must have a negative pregnancy test at baseline. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception (which include oral contraception, injectable or implantable methods, intrauterine devices, double-barrier methods, or condom plus spermatocide) for more than 12 consecutive weeks prior to start of study treatment and are allowed to enroll only if they do not expect to change dose, drug, or discontinue using contraception during the study. 6. Subjects who have been treated with estrogens, androgens, or anti?androgenic agents for more than 12 consecutive weeks prior to the first dose of study product are allowed to enroll as long as they do not expect to change dose, drug, or discontinue use during the study. 7. Subjects who have the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study. |
|
E.4 | Principal exclusion criteria |
1. Female subjects who are pregnant, trying to become pregnant, or who are lactating. 2. Subjects who have any clinically relevant finding at their baseline physical examination or medical history such as severe systemic diseases or diseases of the facial skin other than acne vulgaris. 3. Subjects who have facial hair that may obscure the accurate assessment of acne grade. 4. Subjects who have a history or presence of regional enteritis or inflammatory bowel disease (eg, ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of antibiotic-associated colitis) or similar symptoms. 5. Subjects who have used topical antibiotics on the face or systemic antibiotics within the past 2 and 4 weeks, respectively. 6. Subjects who have used topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra?articular or intra-lesional (other than for facial acne lesions) steroids is acceptable. 7. Subjects who have used systemic retinoids within the past 6 months. 8. Subjects who are using drugs known to be photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the possibility of increased phototoxicity. 9. Subjects who are using neuromuscular blocking agents. Clindamycin has neuromuscular blocking activities, which may enhance the action of other neuromuscular blocking agents. 10. Subjects who have used topical anti-acne medications (eg, BPO, retinoids, azelaic acid, resorcinol, salicylates, sulfacetamide sodium and derivatives, glycolic acid) within the past 2 weeks. 11. Subjects who have used any investigational therapy within 4 weeks of study day 1. 12. Subjects who are using the following types of facial products: astringents, toners, abradants, facials, peels containing glycolic or other acids, masks, washes or soaps containing BPO, sulfacetamide sodium or salicylic acid, non-mild facial cleansers, or moisturizers that contain retinol, salicylic acid, or α- or β-hydroxy acids. 13. Subjects who are using medications that are reported to exacerbate acne (eg, mega-doses of certain vitamins such as vitamin D, vitamin A, and vitamins B2, B6, and B12; haloperidol; halogens such as iodide and bromide; lithium; hydantoin; and phenobarbital) as these may impact efficacy assessments. 14. Subjects who have had a facial procedure (chemical or laser peel, microdermabrasion, artificial ultraviolet [UV] therapy) performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks. 15. Subjects who have a known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, adapalene, clindamycin, BPO, or excipients of the study medication. 16. Subjects who are employees of a clinical research organization involved in the study, or Stiefel Laboratories, or an immediate family member (partner, offspring, parents, siblings, or sibling’s offspring) of an employee, the investigator, or his/her study staff. 17. Subjects who have a member of the same household in this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of percent change in inflammatory lesion count from baseline to week 12 will be analyzed at an alpha level of 0.05 using analysis of covariance (ANCOVA) with treatment, center, and baseline lesion count in the model. The assumption of normality will be verified using the Shapiro-Wilk test with a threshold value of 0.1. If the assumption is not met, the data will be ln-transformed for the primary analysis. If the In-transformed data are also not normal, the data will instead be rank?transformed. Missing values will be imputed using the Last Observation Carried Forward (LOCF) method. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 19 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |